Skip to main content

Taltz Disease Interactions

There are 4 disease interactions with Taltz (ixekizumab).

Moderate

Ixekizumab (applies to Taltz) infections

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Upper respiratory tract infections, oral candidiasis, conjunctivitis, and tinea infections have occurred with the use of ixekizumab. Close monitoring or discontinuation of therapy is recommended in patients with serious infections that do not respond to conventional treatment. It is recommended to restart therapy only until the infection resolves.

References

  1. (2016) "Product Information. Taltz Autoinjector (ixekizumab)." Eli Lilly and Company
Moderate

Ixekizumab (applies to Taltz) inflammatory bowel disease

Moderate Potential Hazard, Moderate plausibility.

Crohn's disease and ulcerative colitis, including exacerbations have occurred during ixekizumab treatment. Caution and close monitoring for onset or exacerbation of inflammatory bowel disease are recommended.

References

  1. (2016) "Product Information. Taltz Autoinjector (ixekizumab)." Eli Lilly and Company
Moderate

Ixekizumab (applies to Taltz) tuberculosis

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Tuberculosis -- Active, History - Tuberculosis, Tuberculosis -- Latent

Patients should be evaluated for tuberculosis (TB) infection prior to ixekizumab treatment. It is recommended to initiate treatment of latent TB prior to administering ixekizumab and to consider anti-TB therapy prior to initiating therapy in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Do not administer this agent to patients with active TB infection. Patients should be monitored closely for signs and symptoms of active TB during and after treatment.

References

  1. (2016) "Product Information. Taltz Autoinjector (ixekizumab)." Eli Lilly and Company
Minor

Ixekizumab (applies to Taltz) renal/hepatic impairment

Minor Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction, Liver Disease

No formal clinical studies of the effect of hepatic or renal impairment on the pharmacokinetics of ixekizumab have been conducted. Care should be taken when prescribing this drug to these patients.

References

  1. (2016) "Product Information. Taltz Autoinjector (ixekizumab)." Eli Lilly and Company

Taltz drug interactions

There are 225 drug interactions with Taltz (ixekizumab).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer